structure-based-drug-design

To choose a docking strategy, evaluate target druggability and binding site flexibility. Use rigid docking for stable sites, but escalate to molecular dynamics or FEP for cryptic binding sites requiring enhanced conformational sampling.

Essential validation steps for reliable virtual screening cascades include redocking known ligands to assess pose reproduction and performing enrichment analysis to ensure the scoring function accurately distinguishes active compounds from decoys.

Use molecular dynamics instead of standard docking for drug design when dealing with cryptic binding sites or significant protein flexibility, where rigid or flexible docking cannot capture the necessary induced-fit conformational changes.

Assess protein druggability by analyzing the binding pocket's volume, hydrophobicity, and structural conservation using the provided crystal structure to determine if the site can accommodate high-affinity small molecule ligands.

Plan a structure-based virtual screening cascade by matching computational cost to decision value, starting with rapid high-throughput docking and progressively applying rigorous scoring functions and molecular dynamics for top-ranked ligands.